Medical Cannabis
Overdue ACMD Report Gets New Deadline as Industry Weighs In
By Ben Stevens, with additional reporting by Nicole Farah, Managing Director of Americana Communications.
CBPMs
9stories
23 Septlast updated
More in CBPMs
- Clinical Research
Cannabis Health Symposium 2025 – Key Takeaways Part 1
On Tuesday, November 25, nearly 200 healthcare professionals, patient advocates, cannabis educators, and industry leaders converged on London’s Conway Hall for the inaugural Cannabis Health Symposium.
- Cultivation
There’s No UK Cannabis Industry Without UK Cultivation
The UK economic growth faces a paradox of two seemingly opposing pressures, yet both may be resolved by moving in the same direction.
- Clinical Research
Accredited Medical Cannabis Symposium Could ‘Benefit Thousands of Patients’, Says Expert
Accredited Medical Cannabis Symposium Could ‘Benefit Thousands of Patients’, Says Expert
- Press releases
Curaleaf Laboratories Backs UK Cannabis Health Symposium with MCCS
Curaleaf Laboratories has been confirmed as headline sponsor of the inaugural Cannabis Health Symposium, taking place on 25 November 2025 at Conway Hall, London.
- UK & Europe
‘Significant Variation in Standards’ Found Across UK Medical Cannabis Pharmacies as ACMD Review Call Closes
The Advisory Council on the Misuse of Drugs (ACMD) has closed its latest call for evidence into the impact of medical cannabis legalisation, in what will mark the most comprehensive review of the UK’s cannabis-based products for medicinal use (CBPM) framework since it was introduced in 2018.
